Candriam S.C.A. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001537014

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeTechnology TiltHigh Turnover how tags are computed

Q3 2026 · 633 positions · Total reported value $22.25B · Top-10 concentration 34.5% · Updated 2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.4% · 21 new · 252 cut · 51 exited

Active Share (vs S&P 500): 37.1% · vs QQQ: 52.6% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -0.6% · vs SPY -2.8% · Prev Value $22.00B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.7% · vs SPY -3.9% · Latest Value $22.25B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Candriam S.C.A. disclosed 633 equity positions with a combined reported value of $22.25B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 34.5% of reported value. HoldingsHub classifies the profile as Large / Technology Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were NVDA ($1.56B), MSFT ($1.32B), AAPL ($1.19B). By sector, the heaviest allocations are Technology 46.8%, Health Care 21.4%. Versus the prior quarter, allocation shifted toward Technology (+2.7pp), Energy (+0.9pp) and away from Financials (-0.5pp), Utilities (-0.6pp).

Versus the prior quarter, Candriam S.C.A. opened 21 new positions, trimmed 252 and fully exited 51, a turnover rate of 47.4% of positions. The portfolio's overlap with the prior quarter was 89% of names.

The largest new positions opened in Q3 2026 were ZBIO ($17.73M), SNDK ($16.87M), GAP ($12.92M).

Of the 51 positions fully exited versus the prior quarter, the largest were SNEX ($46.10M), RARE ($33.42M), CRNX ($30.62M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ZBIO ZENAS BIOPHARMA INC · $17.73M
  • SNDK SANDISK CORP · $16.87M
  • GAP GAP INC · $12.92M
  • LBRX LB PHARMACEUTICALS INC · $10.95M
  • BLTE BELITE BIO INC · $10.71M
  • FTH Faeth Therapeutics Inc · $9.54M
  • ERAS ERASCA INC · $7.24M
  • BTSG BRIGHTSPRING HEALTH SVCS INC · $5.64M

Fully Exited (vs previous quarter)

  • SNEX STONEX GROUP INC · prev qtr: $46.10M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $33.42M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $30.62M
  • CRL CHARLES RIV LABS INTL INC · prev qtr: $23.82M
  • CHE CHEMED CORP NEW · prev qtr: $19.26M
  • TEVA TEVA PHARMACEUTICAL INDS LTD · prev qtr: $18.63M
  • ATAI ATAIBECKLEY INC · prev qtr: $16.00M
  • LEGN LEGEND BIOTECH CORP · prev qtr: $14.57M

Insider Transactions (Form 4)

Latest Candriam S.C.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Candriam S.C.A. is a Luxembourg-based asset management firm founded in 1989, now part of New York Life Investments, with headquarters in Strassen, Luxembourg. The firm employs a responsible investment approach integrating ESG factors across various asset classes.

Investment Approach

Responsible investment with ESG integration, combining quantitative and fundamental research, offering both active and passive investment strategies

Asset Classes

Equities, fixed income, alternatives, multi-asset solutions

Notable Facts

Part of New York Life Investments, strong focus on sustainable investing, acquired in 2018

AUM

$154.7B (SEC Form ADV regulatory figure)

Official disclosures available through SEC filings

Sector Allocation

Technology 46.8%
Health Care 21.4%
Financials 7.0%
Utilities 1.7%
Energy 0.9%
Other 2.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.79M $1.56B 6.99%
6.99%
Reduce
2 2.56M $1.32B 5.93%
5.93%
Add
3 3.55M $1.19B 5.33%
5.33%
Reduce
4 2.33M $803.19M 3.61%
3.61%
Reduce
5 2.37M $592.98M 2.67%
2.67%
Reduce
6 1.64M $578.50M 2.60%
2.60%
Reduce
7 401.21K $465.93M 2.09%
2.09%
Hold
8 421.36K $450.43M 2.02%
2.02%
Hold
9 684.01K $419.98M 1.89%
1.89%
Add
10 403.58K $293.74M 1.32%
1.32%
Add
11 837.88K $286.54M 1.29%
1.29%
Reduce
12 620.96K $284.31M 1.28%
1.28%
Add
13 404.54K $274.08M 1.23%
1.23%
Add
14 676.47K $269.75M 1.21%
1.21%
Reduce
15 679.71K $245.13M 1.10%
1.10%
Add
16 1.82M $244.72M 1.10%
1.10%
Add
17 713.85K $235.36M 1.06%
1.06%
Hold
18 895.79K $235.19M 1.06%
1.06%
Reduce
19 1.47M $214.04M 0.96%
0.96%
Add
20 381.10K $210.93M 0.95%
0.95%
Add
21 1.09M $188.30M 0.85%
0.85%
Reduce
22 1.24M $185.83M 0.83%
0.83%
Add
23 206.76K $177.18M 0.80%
0.80%
Reduce
24 765.66K $176.42M 0.79%
0.79%
Add
25 428.85K $175.02M 0.79%
0.79%
Hold
26 513.20K $170.40M 0.77%
0.77%
Reduce
27 384.90K $153.25M 0.69%
0.69%
Add
28 352.48K $149.12M 0.67%
0.67%
Reduce
29 1.20M $144.81M 0.65%
0.65%
Add
30 1.88M $142.94M 0.64%
0.64%
Reduce
31 516.64K $137.28M 0.62%
0.62%
Add
32 681.61K $133.35M 0.60%
0.60%
Reduce
33 173.15K $131.77M 0.59%
0.59%
Reduce
34 425.92K $121.61M 0.55%
0.55%
Add
35 323.07K $119.03M 0.54%
0.54%
Add
36 440.72K $117.11M 0.53%
0.53%
Add
37 434.20K $115.14M 0.52%
0.52%
Reduce
38 322.48K $114.84M 0.52%
0.52%
Add
39 1.15M $114.20M 0.51%
0.51%
Add
40 212.93K $111.73M 0.50%
0.50%
Add
41 289.24K $106.23M 0.48%
0.48%
Hold
42 311.38K $103.19M 0.46%
0.46%
Add
43 215.89K $98.47M 0.44%
0.44%
Hold
44 336.88K $97.10M 0.44%
0.44%
Reduce
45 412.47K $93.51M 0.42%
0.42%
Add
46 445.69K $91.82M 0.41%
0.41%
Reduce
47 875.84K $89.02M 0.40%
0.40%
Reduce
48 252.30K $88.27M 0.40%
0.40%
Reduce
49 91.92K $87.69M 0.39%
0.39%
Reduce
50 590.17K $86.05M 0.39%
0.39%
Reduce

FAQ

What did Candriam S.C.A. buy in 2026-Q3?

In its 2026-Q3 13F filing, Candriam S.C.A. reported 633 equity positions worth $22.25B in aggregate; its largest disclosed positions were NVDA ($1.56B), MSFT ($1.32B), AAPL ($1.19B).

How large is Candriam S.C.A.'s portfolio?

Candriam S.C.A. reported $22.25B of long equity holdings across 633 positions as of 2026-Q3. Top-10 holdings account for 34.5% of reported value.

What is Candriam S.C.A.'s investment style?

HoldingsHub classifies the portfolio as Large / Technology Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/candriam-s-c-a/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →